Complications profile after robotic pancreatic surgery

Introduction: General acceptance of the robotic platform in pancreatic surgery is poor. One of the main concerns regarding this technique is that the likelihood of complications is greater compared to other approaches. Material and Methods: We performed a retrospective analysis of our database on robotic pancreatic surgery. Results: A total of 22 patients (12 male) underwent robotic pancreatic surgery. 6 pancreatoduodenectomies (PD 27.3%), 12 distal pancreatectomies (DP 54.5%), 2 tumor enucleations (9.1%) and 2 pseudocyst-gastrostomy (9.1%) were performed. The overall operative time was 425 (390–620) min, the median blood loss was 150 ml (70–600). We observed 10/22 (45.4%) overall postoperative morbidity, with 4 grade III to V complications according to the Clavien-Dindo classifi cation system. The Clinically relevant pancreatic fi stula rate was 3/22 (13.6%): 2 in DP group, 1 in the PD group. The reoperation rate was 2/22, one in the PD group, the other in the PG group; while the readmission rate was 18.6%. There was no postoperative death during the 30 days post surgery. Conclusion: Robotic pancreatic surgery seems to be safe and feasible and it is associated with an acceptable risk of complications, low estimated blood loss and low conversion rate.Wprowadzenie: Ogólny stopień akceptacji dla stosowania chirurgii robotowej w chirurgii trzustki jest niski. Jedną z podstawowych barier dla wprowadzania tej techniki jest obawa przed większym niż w przypadku innych technik operacyjnych ryzykiem wystąpienia powikłań pooperacyjnych. Materiał i metody: Przeprowadzono retrospektywną analizę danych szpitalnych dotyczących zabiegów operacyjnych trzustki z dostępu robotowego. Wyniki: Ogółem operowano 22 chorych (w tym 12 mężczyzn) z zastosowaniem systemu robotowego do operacji trzustki. Wykonano 6 pankreatoduodenektomii (27,3%), 12 pankreatektomii obwodowych (54,5%), 2 wyłuszczenia guza (9,1%) oraz 2 zespolenia pseudotorbieli trzustki ze światłem żołądka (9,1%). Czas operacji wyniósł średnio 425 min (390–620 min), a mediana utraty krwi – 150 ml (70–600 ml). Powikłania pooperacyjne stwierdzono u 10 z 22 chorych (45,4%) przy czym u 4 wystąpiły powikłania w stopniu III–V według skali Claviena-Dindo. Klinicznie istotna przetoka trzustkowa wystąpiła u 3 z 22 chorych (13,6%), w tym u 2 chorych po resekcji obwodowej trzustki i u 1 po pankreatoduodenektomii. Reoperacje były konieczne u 2 z 22 chorych: jedna po zabiegu pankreatoduodenektomii i jedna po zespoleniu pseudotorbieli ze światłem żołądka. Odsetek ponownych przyjęć do szpitala wyniósł 18,6%. Nie stwierdzono zgonów w okresie 30 dni po zabiegu operacyjnym. Wnioski: Robotowa chirurgia trzustki wydaje się być techniką bezpieczną i wykonalną przy akceptowalnym ryzyku powikłań pooperacyjnych, niskiej śródoperacyjnej utracie krwi oraz niskim ryzyku konwersji

OBTAINING MESENCHYMAL STEM CELLS FROM ADIPOSE TISSUE OR MURIN ORIGIN: EXPERIMENTAL STUDY.

The aim of this study was to isolate and characterize rat adipose Derived Mesenchymal Stem Cells (AD-MSCs) in order to evaluate their proliferative potential and their ability to different cell types. AD-MSCs and Derived Mesenchymal Stem Cells (BM-MSCs) have the same characteristic in terms of plasticity. The advantage of adipose tissue is that it is an easier accessible source and it offers a large amount of MSCs by less invasive surgical tecniques. MSCs were obtained from subcutaneous adipose tissue of Wistar rats. first of all microbiological controls were made to exclude the presence of bacteria of fungi in then tissue. Adipose tissue was mechanically and enzimatically fragmented and stromal cell fraction was seeded in adherent culture flasks in DMEM 20% FBS. After 48 h the medium was replaced. Cells were characterized by evaluating:1)their ability tho adhere to the plastic; 2) the clonogenic potential by Colony Forming Unit (CFU) assay, 3) their ability to differentiate in 3 mesodermal lineages (adipocytes, osteocytes and chondrocytes). AD-MSCs are able to differentiate in adipocytes, osteocytes and chondrocytes as confirmed by oil red'O staining, von Kossa staining and histological analuysis respectively. This first characterization is essential for the second part of our study in which we are planning to use AD-MSCs in vivo to restore renal function after an induced ischemic damage in experimental animals

Timing Analysis of the 2022 Outburst of the Accreting Millisecond X-Ray Pulsar SAX J1808.4-3658: Hints of an Orbital Shrinking

We present a pulse timing analysis of NICER observations of the accreting millisecond X-ray pulsar SAX J1808.4-3658 during the outburst that started on 2022 August 19. Similar to previous outbursts, after decaying from a peak luminosity of ≃1 × 1036 erg s-1 in about a week, the pulsar entered a ~1 month long reflaring stage. Comparison of the average pulsar spin frequency during the outburst with those previously measured confirmed the long-term spin derivative of ν˙SD=−(1.15±0.06)×10−15 Hz s-1, compatible with the spin-down torque of a ≈1026 G cm3 rotating magnetic dipole. For the first time in the last twenty years, the orbital phase evolution shows evidence for a decrease of the orbital period. The long-term behavior of the orbit is dominated by an ~11 s modulation of the orbital phase epoch consistent with a ~21 yr period. We discuss the observed evolution in terms of a coupling between the orbit and variations in the mass quadrupole of the companion star

Precise measurement of the W-boson mass with the CDF II detector

We have measured the W-boson mass MW using data corresponding to 2.2/fb of integrated luminosity collected in proton-antiproton collisions at 1.96 TeV with the CDF II detector at the Fermilab Tevatron collider. Samples consisting of 470126 W->enu candidates and 624708 W->munu candidates yield the measurement MW = 80387 +- 12 (stat) +- 15 (syst) = 80387 +- 19 MeV. This is the most precise measurement of the W-boson mass to date and significantly exceeds the precision of all previous measurements combined

Search for the rare decays B0→J/ψγB^{0}\to J/\psi \gamma and Bs0→J/ψγB^{0}_{s} \to J/\psi \gamma

A search for the rare decay of a $B^{0}$ or $B^{0}_{s}$ meson into the final state $J/\psi\gamma$ is performed, using data collected by the LHCb experiment in $pp$ collisions at $\sqrt{s}=7$ and $8$ TeV, corresponding to an integrated luminosity of 3 fb$^{-1}$. The observed number of signal candidates is consistent with a background-only hypothesis. Branching fraction values larger than $1.7\times 10^{-6}$ for the $B^{0}\to J/\psi\gamma$ decay mode are excluded at 90% confidence level. For the $B^{0}_{s}\to J/\psi\gamma$ decay mode, branching fraction values larger than $7.4\times 10^{-6}$ are excluded at 90% confidence level, this is the first branching fraction limit for this decay.Comment: All figures and tables, along with any supplementary material and additional information, are available at https://lhcbproject.web.cern.ch/lhcbproject/Publications/LHCbProjectPublic/LHCb-PAPER-2015-044.htm

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status

Family history of cancer (FHC) is a hallmark of cancer risk and an independent predictor of outcome, albeit with uncertain biologic foundations. We previously showed that FHC-high patients experienced prolonged overall (OS) and progression-free survival (PFS) following PD-1/PD-L1 checkpoint inhibitors. To validate our findings in patients with NSCLC, we evaluated two multicenter cohorts of patients with metastatic NSCLC receiving either first-line pembrolizumab or chemotherapy. From each cohort, 607 patients were randomly case-control matched accounting for FHC, age, performance status, and disease burden. Compared to FHC-low/negative, FHC-high patients experienced longer OS (HR 0.67 [95% CI 0.46-0.95], p\u2009=\u20090.0281), PFS (HR 0.65 [95% CI 0.48-0.89]; p\u2009=\u20090.0074) and higher disease control rates (DCR, 86.4% vs 67.5%, p\u2009=\u20090.0096), within the pembrolizumab cohort. No significant associations were found between FHC and OS/PFS/DCR within the chemotherapy cohort. We explored the association between FHC and somatic DNA damage response (DDR) gene alterations as underlying mechanism to our findings in a parallel cohort of 118 NSCLC, 16.9% of whom were FHC-high. The prevalence of\u2009 65\u20091 somatic DDR gene mutation was 20% and 24.5% (p\u2009=\u20090.6684) in FHC-high vs. FHC-low/negative, with no differences in tumor mutational burden (6.0 vs. 7.6 Mut/Mb, p\u2009=\u20090.6018) and tumor cell PD-L1 expression. FHC-high status identifies NSCLC patients with improved outcomes from pembrolizumab but not chemotherapy, independent of somatic DDR gene status. Prospective studies evaluating FHC alongside germline genetic testing are warranted

Corrigendum: The silent epidemic of diabetic ketoacidosis at diagnosis of type 1 diabetes in children and adolescents in italy during the covid-19 pandemic in 2020(Front. Endocrinol., (2022), 13, (878634), 10.3389/fendo.2022.878634)

[This corrects the article .]

Watchful Waiting After Radiological Guided Drainage of Intra-abdominal Abscess in Patients With Crohn's Disease Might Be Associated With Increased Rates of Stoma Construction

Background: Management of spontaneous intra-abdominal abscess (IAA) in patients with Crohn's disease (CD) with radiologically guided percutaneous drainage (PD) was debated. Methods: This is a secondary analysis from a multicenter, retrospective cohort study of all the patients with CD who underwent PD followed by surgery at 19 international tertiary centers. Results: Seventeen patients (4.8%) who did not undergo surgery after PD were compared to those who had PD followed by surgical intervention 335/352 (95.2%). Patients who had PD without surgery were those with longer disease duration, more frequently had previous surgery for CD (laparotomies/laparoscopies), enteric fistula, on steroid treatment before and continue to have it after PD. Patients who had PD without subsequent surgical resection had a higher risk of stoma construction at later stages 8/17 (47.1%) versus 90/326 (27.6%) (P < .01). Patients with PD with no subsequent surgery had numerically higher rates of abscess recurrence 5/17 (29.4%) compared to those who had PD followed by surgery 45/335 (13.4%) the difference was not statistically significant (P = .07). Conclusions: Even with the low number of patients enrolled in this study who had PD of IAA without subsequent surgery, the findings indicate a markedly worse prognosis in terms of recurrence, length of stay, readmission, and stoma construction. Watchful waiting after PD to treat patients with spontaneous IAA might be indicated in selected patients with poor health status or poor prognostic factors

Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

Long noncoding RNAs (lncRNAs) are commonly dys-regulated in tumors, but only a handful are known toplay pathophysiological roles in cancer. We inferredlncRNAs that dysregulate cancer pathways, onco-genes, and tumor suppressors (cancer genes) bymodeling their effects on the activity of transcriptionfactors, RNA-binding proteins, and microRNAs in5,185 TCGA tumors and 1,019 ENCODE assays.Our predictions included hundreds of candidateonco- and tumor-suppressor lncRNAs (cancerlncRNAs) whose somatic alterations account for thedysregulation of dozens of cancer genes and path-ways in each of 14 tumor contexts. To demonstrateproof of concept, we showed that perturbations tar-geting OIP5-AS1 (an inferred tumor suppressor) andTUG1 and WT1-AS (inferred onco-lncRNAs) dysre-gulated cancer genes and altered proliferation ofbreast and gynecologic cancer cells. Our analysis in-dicates that, although most lncRNAs are dysregu-lated in a tumor-specific manner, some, includingOIP5-AS1, TUG1, NEAT1, MEG3, and TSIX, synergis-tically dysregulate cancer pathways in multiple tumorcontexts

Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas

Although theMYConcogene has been implicated incancer, a systematic assessment of alterations ofMYC, related transcription factors, and co-regulatoryproteins, forming the proximal MYC network (PMN),across human cancers is lacking. Using computa-tional approaches, we define genomic and proteo-mic features associated with MYC and the PMNacross the 33 cancers of The Cancer Genome Atlas.Pan-cancer, 28% of all samples had at least one ofthe MYC paralogs amplified. In contrast, the MYCantagonists MGA and MNT were the most frequentlymutated or deleted members, proposing a roleas tumor suppressors.MYCalterations were mutu-ally exclusive withPIK3CA,PTEN,APC,orBRAFalterations, suggesting that MYC is a distinct onco-genic driver. Expression analysis revealed MYC-associated pathways in tumor subtypes, such asimmune response and growth factor signaling; chro-matin, translation, and DNA replication/repair wereconserved pan-cancer. This analysis reveals insightsinto MYC biology and is a reference for biomarkersand therapeutics for cancers with alterations ofMYC or the PMN